Clinical trials: Tuberculosis Infection, Latent
Tuberculosis (TB), Tuberculosis Infection, Latent
Screening With Portable X-rays for Rapid Recognition of TB
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
- Trial name
- SPOT-TB (NCT07737275)
- Testing
- Mobile chest radiography for tuberculosis screening
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Tuberculosis
Treatment of Latent Tuberculosis Infection With Isoniazid
The purpose of this study is to study the effect that treatment of dormant tuberculosis infection has on the immunological system.
- Trial name
- NCT00293228
- Testing
- Isoniazid
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
TUBERCULOSIS
Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis
Methodology This is a single-center study carried out as part of routine patient care. The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.
- Trial name
- TUBIGRA (NCT06485895)
- Testing
- test IGRA, TEST QUATIFERON TB Gold Plus
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Latent Tuberculosis, Diabetes Mellitus, Type 2
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
This study will be investigating the effect of latent tuberculosis infection (LTBI) treatment on glucose tolerance and low-grade inflammation.
- Trial name
- NCT04830462
- Testing
- Rifampicin 300 Mg Oral Capsule, Isoniazid 300 Mg ORAL TABLET
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Herlev and Gentofte Hospital
Latent Tuberculosis
Tuberculosis Clinical Trials Consortium Study 35
Hypotheses: Rifapentine (given as water-dispersible monolayer and/or fixed dose combination with isoniazid) dosing in HIV-infected and uninfected children ≤ 12 years of age with latent TB infection (LTBI) or with exposure to…
- Trial name
- NCT03730181
- Testing
- Rifapentine, Isoniazid
- Where
- South Africa
- Volunteers
- 69 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis Infection, Isoniazid Adverse Reaction
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.
- Trial name
- NCT05413551
- Testing
- Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- Stanford University
Latent Tuberculosis Infection
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.
- Trial name
- NCT00449345
- Testing
- Blood test for Quantiferon-GOLD assay
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assuta Hospital Systems
Healthy, Latent Tuberculosis Infection (LTBI)
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Background: Tuberculosis (TB) is a lung disease. It is caused by inhaling a type of airborne bacterium. Tuberculin Purified Protein Derivative (PPD) is used to test for TB exposure. It is usually injected under a person s skin.
- Trial name
- NCT05027958
- Testing
- Tuberculin Purified Protein Derivative
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Gene Expression, Gene Expression Profiling
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA
Febrile illness is a common condition, particularly among young patients and it is crucial to have an early triage of patients according to various aetiologies to enable appropriate treatment.
- Conditions
- Gene Expression, Gene Expression Profiling, Infection, Viral Diseases
- Trial name
- NCT06838780
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Latent Tuberculosis Infection, Tuberculosis
Diagnosis of Tuberculosis Infection in HIV Co-infected Children
Background: The TB and HIV epidemics are closely linked in developing countries, where 450,000 children die from HIV annually. TB is a major cause of death in HIV-infected children and is reversing gains made in child survival.
- Conditions
- Latent Tuberculosis Infection, Tuberculosis, HIV Infections
- Trial name
- ThrasherIGRA (NCT00541294)
- Where
- South Africa
- Volunteers
- 250 people
- Sponsor
- Case Western Reserve University
To Determine the Prevalence of Latent Tuberculosis in Each Group, To Monitor the Occurrence of Active Tuberculosis
Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis
To follow-up the latent tuberculosis infection and evaluate the risk of developing active tuberculosis in patients with severe chronic kidney disease or receiving long-term dialysis
- Trial name
- NCT01685086
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Tuberculin Skin Test
Self-Assessment Tuberculin Skin Test
The research team/investigator/nurse/professional health care workers will teach the participants how to read the results for TST test.
- Trial name
- ISAT (NCT03835832)
- Testing
- The participants do not receive any intervention for this study
- Where
- 2 sites in Thailand
- Volunteers
- 215 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Tuberculosis Infection
Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
It is intended for patients who have been admitted to the outpatient or emergency room or are hospitalized For patients who diagnose pulmonary tuberculosis or extrapulmonary tuberculosis using Xpert TB/RIF, additionally, diagnose…
- Trial name
- New Assay TB (NCT04988984)
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Asan Medical Center
Latent Tuberculosis Infection
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
Though still an endemic area, the incidence of tuberculosis (TB) in Taiwan is decreasing in recent years. Further reduction in TB incidence, or even elimination should rely on treatment for LTBI.
- Trial name
- NCT01398618
- Testing
- 4-month rifampin vs. 9-month isoniazid
- Where
- 2 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Acquired Immunodeficiency Syndrome, Histoplasmosis AIDS
Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City
In Mexico City, the main cause of mortality among people living with HIV (PLHIV) continues to be opportunistic infections (OIs). Early detection of OIs allows their timely treatment and improves their prognosis.
- Conditions
- Acquired Immunodeficiency Syndrome, Histoplasmosis AIDS, Tuberculosis Infection, Cryptococcal Meningitis
- Trial name
- PREVALIOCDMX (NCT05685641)
- Testing
- Histoplasma Urine Antigen Lateral Flow Antigen test, Cryptococcal Lateral Flow Antigen test, Tuberculosis-lipoarabinomannan Lateral Flow Antigen test
- Where
- 4 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Tuberculosis Infection, HIV Infections
Computer Aided Screening for Tuberculosis in Low Resource Environments
People living with HIV (PLHIV) who require admission to hospital in WHO Africa region have poor outcomes. TB is very common in this group, but can be difficult to diagnose.
- Trial name
- CASTLE (NCT04545164)
- Testing
- CAD4TB, FujiLAM
- Where
- Malawi
- Volunteers
- 498 people
- Sponsor
- London School of Hygiene and Tropical Medicine
HIV Infected Population With Latent Tuberculosis
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
People with human immunodeficiency virus (HIV) often take several medicines to control HIV. Dolutegravir and darunavir boosted with cobicistat are HIV medicines that people may take.
- Trial name
- NCT02771249
- Testing
- rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)